BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.
In the News
The Atlantic “WHAT’S NEXT?”: Hacking the Genome
Rachel Haurwitz, President and CEO of Caribou Biosciences, is interviewed by Ross Andersen, Senior Editor of The Atlantic, at the “WHAT’S NEXT?” summit. She discusses the impact of CRISPR for the scientific community, the big issues in gene editing, and the future of this technology for therapeutics and agriculture.
PBS: Editing Out Pesticides
This summer, more than a million tons of chardonnay grapes are plumping on manicured vineyards around the world. The grapes make one of the most popular white wines, but their juicy fruit and luscious leaves are also targets for diseases such as downy mildew, a stubborn fungus-like parasite.